NASDAQ:INCY
Incyte Corporation Stock News
$54.08
+0.320 (+0.595%)
At Close: May 06, 2024
20 value stocks whose growth potential is overlooked by investors
05:06pm, Tuesday, 13'th Sep 2022 MarketWatch
Value stocks have held up better than growth stocks this year, and that trend may continue, according to analysts.
Pfizer (PFE) Alopecia Drug Filings Get Accepted by FDA, EMA
04:22pm, Monday, 12'th Sep 2022 Zacks Investment Research
FDA accepts Pfizer's (PFE) NDA for ritlecitinib for treating severe alopecia areata. The EMA also accepts the MAA for a similar patient population.
Should You Invest in the Invesco S&P 500 Equal Weight Health Care ETF (RYH)?
10:20am, Monday, 12'th Sep 2022 Zacks Investment Research
Sector ETF report for RYH
Trading The Top 10 Stocks From 40 Large Hedge Funds: Trading Update 9/4/2022
04:24am, Monday, 05'th Sep 2022 Seeking Alpha
A strategy selecting 10 of the 50 stocks, equally weighted, would have increased total return to 178.0%, an active return of 61.6% vs. SPY.
Incyte (INCY) Down 2.9% Since Last Earnings Report: Can It Rebound?
03:31pm, Thursday, 01'st Sep 2022 Zacks Investment Research
Incyte (INCY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Incyte (INCY) Down 2.9% Since Last Earnings Report: Can It Rebound?
01:09pm, Thursday, 01'st Sep 2022
Incyte (INCY) reported earnings 30 days ago. What's next for the stock?
Biotech Stock Roundup: BMY's Study Update, INCY's Drug Label Expansion, MRNA News
05:22pm, Wednesday, 31'st Aug 2022 Zacks Investment Research
Regulatory updates from Bristol Myers (BMY) and Incyte (INCY) are a few key highlights from the biotech sector during the past week.
Incyte (INCY) Gets FDA Nod for Label Expansion of Pemazyre
03:31pm, Monday, 29'th Aug 2022 Zacks Investment Research
Incyte (INCY) obtains FDA approval for Pemazyre for a second indication - the treatment of adults with relapsed or refractory myeloid/lymphoid neoplasms with FGFR1 rearrangement.
Incyte (INCY) Gets FDA Nod for Label Expansion of Pemazyre
12:47pm, Monday, 29'th Aug 2022
Incyte (INCY) obtains FDA approval for Pemazyre for a second indication - the treatment of adults with relapsed or refractory myeloid/lymphoid neoplasms with FGFR1 rearrangement.
Incyte to Present at Upcoming Investor Conference
08:00am, Tuesday, 23'rd Aug 2022
WILMINGTON, Del.--(BUSINESS WIRE)--Incyte (Nasdaq:INCY) announced today that it will present at the Morgan Stanley 20th Annual Global Healthcare Conference on Monday, September 12, 2022 at 12:30 p.m.
Novartis (NVS) NSCLC Study Fails to Meet Primary Endpoint
04:00pm, Tuesday, 16'th Aug 2022 Zacks Investment Research
Novartis (NVS) suffers a setback as canakinumab fails to meet the primary goal in yet another study for lung cancer.
4 Growth Stocks to Buy and Hold Forever
10:20am, Friday, 12'th Aug 2022 The Motley Fool
Some businesses are just bigger than any economic headwind and don't run the risk of obsolescence.
4 Growth Stocks to Buy and Hold Forever
06:20am, Friday, 12'th Aug 2022
Some businesses are just bigger than any economic headwind and don't run the risk of obsolescence.
Benzinga's Top Ratings Upgrades, Downgrades For August 3, 2022
02:38pm, Wednesday, 03'rd Aug 2022 Benzinga
Upgrades
Bernstein upgraded the previous rating for Cognex Corp (NASDAQ:CGNX) from Market Perform to Outperform. In the second quarter, Cognex showed an EPS of $0.41, compared to $0.43 from the year-
Incyte's (INCY) Earnings and Revenues Surpass Estimates in Q2
03:47pm, Tuesday, 02'nd Aug 2022 Zacks Investment Research
Incyte's (INCY) earnings and revenues trump estimates in the second quarter of 2022. The company raises the bottom end of full-year Jakafi's net product revenue guidance.
